|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 377.04 USD | -1.89% |
|
+9.45% | +15.26% |
| Feb. 06 | Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating | MT |
| Feb. 06 | Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 207B | |||||
| 947B | |||||
| 578B | |||||
| 395B | |||||
| 367B | |||||
| 303B |
- Stock Market
- Equities
- AMGN Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
